Back to companies

Oncopeptides AB: Overview

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward

Select Item

Oncopeptides AB (Oncopeptides) is a biotechnology company that carries out the research, development, and commercialization of targeted therapies for difficult-to-treat cancers. Its activities include developing innovative drug candidates using its proprietary technology platforms. The company's lead product includes Melflufen, a peptide drug conjugate, which is used to treat hematological cancer and relapsed and refractory multiple myeloma. Oncopeptides utilizes its proprietary peptide drug candidate platform PDC to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells and small polypeptide based killer engagers (SPiKE) for the treatment of multiple myeloma. The company operates in Germany, the US and Sweden. Oncopeptides is headquartered in Stockholm, Sweden.

 Gain a 360-degree view of Oncopeptides AB and make more informed decisions for your business Gain a 360-degree view of Oncopeptides AB and make more informed decisions for your business Register your interest
Headquarters Sweden
Address Luntmakargatan 46, 7th Floor, Stockholm, 11137
Website www.oncopeptides.se
Telephone 46 8 6152040
No of Employees 75
Industry Pharmaceuticals and Healthcare
Ticker Symbol & Exchange ONCO (STO)
Revenue (2025) $6.7M 124.7% (2025 vs 2024)
EPS XYZ
Net Income (2025) XYZ 12.3% (2025 vs 2024)
Market Cap* $62.4M
Net Profit Margin (2025) XYZ 61.0% (2025 vs 2024)
* As of and is in US$
View Oncopeptides AB financials
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Register your interest

Oncopeptides AB premium industry data and analytics

20+

Catalyst Calendar

Proactively evaluate Oncopeptides AB’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

16+

Clinical Trials

Determine Oncopeptides AB go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

6

Pipeline Drugs

Identify which of Oncopeptides AB’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

3

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

1

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

1

Marketed Drugs

Understand Oncopeptides AB’s commercialized product portfolio to stay one step ahead of the market.

Products and Services

Products Brands
Pipeline Pepaxti
Melflufen: Hematological Cancer and Relapsed and Refractory Multiple Myeloma
Pepaxti
XYZ
XYZ
XYZ
Understand Oncopeptides AB portfolio and identify potential areas for collaboration Understand Oncopeptides AB portfolio and identify potential areas for collaboration Register your interest
Image for loader

Competitor Comparison

Key Parameters Oncopeptides AB Swedish Orphan Biovitrum AB BioGaia AB Sprint Bioscience AB Hansa Biopharma AB
Headquarters Sweden Sweden Sweden Sweden Sweden
City Stockholm Stockholm Stockholm Huddinge Lund
State/Province - Stockholm - - -
No. of Employees 75 1,888 238 29 133
Entity Type Public Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Register your interest
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Register your interest
Executives
Name Position Board Since Age
Per Wold-Olsen Chairman Executive Board 2018 78
Sofia Heigis Chief Executive Officer Senior Management 2023 45
Henrik Bergentoft Chief Financial Officer Senior Management 2023 51
Eva Nordstrom Chief Operating Officer Senior Management 2012 -
David Augustsson Director - IR and Communications Senior Management 2023 41
Non Dignissim Eros Proin vel Convallis 2026 XY
Non Dignissim Eros Proin vel Convallis 2026 XY
Non Dignissim Eros Proin vel Convallis 2026 XY
Gain insight into Oncopeptides AB key executives to enhance your sales strategy Gain insight into Oncopeptides AB key executives to enhance your sales strategy Register your interest
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Why are you leaving?